Brain region specificity of 3-nitropropionic acid-induced vulnerability of neurons involves cytochrome c oxidase

Neurochemistry International

Volumn 57, Issue 3, 2010, Pages 297-305

  Singh, Shilpee ^a   Misiak, Magdalena ^a   Beyer, Cordian ^a   Arnold, Susanne ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Cortex; Cytochrome c oxidase isoform IV 2; Neuron; Oxidative stress; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE TRIPHOSPHATE; CYTOCHROME C OXIDASE; PEROXIDE; REACTIVE OXYGEN METABOLITE; 3-NITROPROPIONIC ACID; ADENOSINE DIPHOSPHATE; CONVULSANT AGENT; ISOENZYME; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN CORTEX; BRAIN REGION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; MITOCHONDRION; MOUSE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BRAIN LEVEL; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; METABOLISM; NECROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN CHEMISTRY; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CONVULSANTS; CORPUS STRIATUM; ELECTRON TRANSPORT COMPLEX IV; EXCITATORY POSTSYNAPTIC POTENTIALS; ISOENZYMES; MICE; MICE, INBRED BALB C; NECROSIS; NEURONS; NITRO COMPOUNDS; PROPIONIC ACIDS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; PROPIONATES;

EID: 77955093673     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.06.008     Document Type: Article

References (51)

1. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
2. Arnold S., Kadenbach B. Cell respiration is controlled by ATP, an allosteric inhibitor of cytochrome-c oxidase. Eur. J. Biochem. 1997, 249:350-354.
3. Arnold S., Kadenbach B. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. FEBS Lett. 1999, 443:105-108.
4. Ayala A., Venero J.L., Cano J., Machado A. Mitochondrial toxins and neurodegenerative diseases. Front. Biosci. 2007, 12:986-1007.
5. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58:495-505.
6. Brewer G.J. Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J. Neurosci. Res. 1995, 42:674-683.
7. Brouillet E., Condé F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
8. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 15:21-40.
9. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
10. Cadenas E., Boveris A., Ragan C.I., Stoppani A.O. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch. Biochem. Biophys. 1977, 180:248-257.
11. Cirillo G., Maggio N., Bianco M.R., Vollono C., Sellitti S., Papa M. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. Neurochem. Int. 2010, 56:152-160.
12. de la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47:516-525.
13. Dröse S., Brandt U. The mechanism of mitochondrial superoxide production by cytochrome bc1 complex. J. Biol. Chem. 2008, 283:21649-21654.
14. Duran-Vilaregut J., Del Valle J., Manich G., Junyent F., Camins A., Pallàs M., Pelegrí C., Vilaplana J. Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes. Neurochem. Int. 2010, 56:443-450.
15. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., Richardson E.P. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1987, 46:12-27.
16. Geddes J.W., Bondada V., Pang Z. Mechanism of 3-nitroproprionic acid neurotoxicity. Mitochondrial Inhibitors and Neurodegenerative Disorders 2000, 107-120. Humana Press, Totowa, NJ. P.R. Sandberg, H. Nishino, C.V. Borlongan (Eds.).
17. 2+ in transgenic Huntington disease rats. J. Biol. Chem. 2008, 283:30715-30724.
18. Grossman L.I., Lomax M.I. Nuclear genes for cytochrome c oxidase. Biochim. Biophys. Acta 1997, 1352:174-192.
19. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
20. Hoang T.Q., Bluml S., Dubowitz D.J., Moats R., Kopyov O., Jacques D., Ross B.D. Quantitative proton decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998, 50:1033-1040.
21. Horvat S., Beyer C., Arnold S. Effect of hypoxia on the transcription pattern of subunit isoforms and the kinetics of cytochrome c oxidase in cortical astrocytes and cerebellar neurons. J. Neurochem. 2006, 99:937-951.
22. Hüttemann M., Kadenbach B., Grossman L.I. Mammalian subunit IV isoforms of cytochrome c oxidase. Gene (Amst.) 2001, 267:111-123.
23. Jenkins B.G., Koroshetz W.J., Beal M.F., Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993, 43:689-2695.
24. Jenkins B.G., Rosas H.D., Chen Y.C., Makabe T., Myers R., MacDonald M., Rosen B.R., Beal M.F., Koroshetz W.J. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998, 50:1357-1365.
25. Kadenbach B., Hüttemann M., Arnold S., Lee I., Bender E. Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Rad. Biol. Med. 2000, 29:211-221.
26. Kadenbach B., Arnold S., Lee I., Huttemann M. The possible role of cytochrome c oxidase in stress-induced apoptosis and degenerative diseases. Biochim. Biophys. Acta 2004, 1655:400-408.
27. Kajta M., Trotter A., Lasoń W., Beyer C. Impact of 17β-estradiol on cytokine-mediated apoptotic effects in primary hippocampal and neocortical cell cultures. Brain Res. 2006, 1116:64-74.
28. Kasparova S., Sumbalova Z., Bystricky P., Kucharska J., Liptaj T., Mlynarik V., Gvozdjakova A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 2006, 48:93-99.
29. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41:160-165.
30. Landles, C., Bates, G.P., 2004. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Reports 5, pp. 958-963.
31. Marcinek D.J. Mitochondrial dysfunction measured in vivo. Acta Physiol. Scand. 2004, 182:343-352.
32. Martin J.B., Gusella J.F. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 1986, 315:1267-1276.
33. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 1998, 18:156-163.
34. Nishino H., Shimano Y., Kumazaki M., Sakurai T. Chronically administered 3-nitropropionic acid induces striatal lesion attributed to dysfunction of the blood-brain barrier. Neurosci. Lett. 1995, 186:161-164.
35. Oláh J., Klivényi P., Gardián G., Vécsei L., Orosz F., Kovacs G.G., Westerhoff H.V., Ovádi J. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J. 2008, 275:4740-4755.
36. Oliveira J.M.A., Jekabsons M.B., Chen S., Lin A., Rego A.C., Gonçalves J., Ellerby L.M., Nicholls D.G. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 2007, 101:241-249.
37. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., Usha R. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem. Int. 2009, 55:431-437.
38. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
39. Perez-De La Cruz V., Santamaria A. Integrative hypothesis for Huntington's disease: a brief review on experimental evidence. Physiol. Res. 2006, 56:513-526.
40. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48:356-373.
41. Sanchez-Pernaute R., Garcia-Segura J.M., del Barrio Alba A., Viano J., de Yebenes J.G. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999, 53:806-812.
42. Saulle E., Gubellini P., Picconi B., Centonze D., Tropepi D., Pisani A., Morari M., Marti M., Rossi L., Papa M., Bernardi G., Calabresi P. Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Mol. Cell. Neurosci. 2004, 25:9-20.
43. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F., Greenamyre J.T., Snyder S.H., Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 1999, 5:1194-1198.
44. Sawa A., Tomoda T., Bae B.I. Mechanisms of neuronal cell death in Huntington's disease. Cytogenet. Genome Res. 2003, 100:287-295.
45. Schapira A.H. Mitochondrial function in Huntington's disease: clues for pathogenesis and prospects for treatment. Ann. Neurol. 1997, 41:141-142.
46. Schmidt U., Pilgrim C., Beyer C. Differentiative effects of dopamine on striatal neurons involve stimulation of the cAMP/PKA pathway. Mol. Cell. Neurosci. 1998, 11:9-18.
47. Seong I.S., Ivanova E., Lee J.M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 2005, 14:2871-2880.
48. Singh S., Misiak M., Beyer C., Arnold S. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes. Glia 2009, 57:1480-1491.
49. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
50. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
51. Vis J.C., Verbeek M.M., De Waal R.M., Ten Donkelaar H.J., Kremer H.P. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Neuropathol. Appl. Neurobiol. 1999, 25:513-521.